Boan Biotech Signed A Strategic Cooperation Agreement with GenScript Biotech, Targeting the Field of Cell Therapy

Nanjing, May 12, 2023——Boan Biotech signed a strategic cooperation agreement with GenScript Biotech Corporation (hereinafter referred to as GenScript Biotech) in Nanjing, reached a cooperation on the development and production of GenCircle^TM dsDNA, a novel small circular double-stranded DNA vector without antibiotic resistant marker that is a critical raw material in the field of gene and cell therapy. Boan Biotech will purchase GenCircleTM dsDNA at a scientific research level of GMP from GenScript to further enhance the R&D efficiency of independently developed cell drug preparation platforms “STEALTH CAR-T^TM” and “ReceptorTAC^TM”, and accelerate the development process of non-viral vector cell therapy products, thus setting out for the field of cell therapy from a high starting point.

Ms. Jiang Hua, CEO of Boan Biotech（Left）and Ms. Shao Weihui, CEO of GenScript Biotech（Right）

According to the Agreement, GenScript Biotech will offer specialized and customized services in support of the development, production and QC testing of GenCircle^TM dsDNA, so as to promote the development of Boan Biotech’s non-viral vector cell therapy products. At the same time, Boan Biotech and GenScript Biotech will strengthen cooperation in all aspects of life science services, including critical raw materials for gene editing, nucleic acid synthesis, molecular biology services, peptide synthesis, customized protein expression and purification, etc.

Within the field of cell therapy, Boan Biotech focuses on a new generation of enhanced and adjustable CAR-T, and leverages non-viral gene modification system technology to develop novel CAR-T products for the treatment of solid tumors. The cell drug preparation platforms “STEALTH CAR-T^TM” and “ReceptorTAC^TM” independently developed by Boan Biotech are differentiated innovative cell technology platforms curated based on non-viral gene delivery system, enhanced CAR-T therapy technology and non-gene editing protein degradation technology. With the two platforms, Boan Biotech aspires to, through a series of technical layouts, make new breakthroughs in the clinical application of cell therapies for treatment of solid tumors.

Ms. Jiang Hua, CEO of Boan Biotech, noted, “Boan Biotech has rich experience accumulation in the fields of monoclonal antibody, bispecific antibody, ADC and other macromolecular therapeutics. While continuously accelerating innovative drug discovery within the scopes of existing technologies, enhancing the efficiency of R&D pipelines and strengthening commercial production and marketing capabilities, Boan Biotech also focuses on the future, making active presence in the field of cell therapy, unlocking new growth potentials, and sparing unremitting efforts to achieve the goal of becoming a ‘world-leading bio-pharmaceutical company’. GenScript Biotech is a world-leading life science service provider. We fully recognize the services and products that GenScript provides, and expect that our joint efforts will make Boan Biotech’s cell therapy products benefiting patients in clinical practice as soon as possible.”

Ms. Shao Weihui, CEO of GenScript Biotech, appreciated Boan Biotech for the trust and support to GenScript Biotech and expressed her pleasure to have in-depth strategic cooperation with such an excellent team as Boan Biotech. GenScript Biotech has always adhered to the concept of “customer first”, and continuously upgraded from supporting early scientific research to matching downstream applications by constant innovation and forging ahead around customer needs. Gene cell therapy is a strategic direction of GenScript Biotech’s key layout, and it is looking forward to making its own contributions in this field with premium services and quality products, and practicing the corporate mission of “making people and nature healthier through biotechnology”.

###

About Boan Biotech

Boan Biotech (6955.HK) is a fully-integrated biopharmaceutical company developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform, ADC Technology Platform and Cell Therapy Platform.

Boan Biotech operates across the entire value chain of the industry covering antibody discovery, cell line development, upstream and downstream process development, analytical and bio-analytical method development, technology transfer, non-clinical research, clinical research, regulatory affairs and registration, and commercial production. In the cell therapy field, Boan Biotech focuses on a new generation of enhanced and regulated CAR-T technology, developing safer, more effective, and affordable treatments for patients.

Boan Biotech’s portfolio includes two commercial products. Its pipeline includes multiple novel biologics as drug candidates protected for their international intellectual property rights and a number of biosimilar candidates. In addition to China, the company is also developing biopharmaceutical products in overseas markets, including the U.S. and the EU. With a differentiated portfolio and well-established commercial capabilities, Boan Biotech operates across the industry’s value chain from research and development to manufacturing and commercialization. This has laid a solid foundation for its long-term, high-quality growth.

About GenScript Biotech

GenScript Biotech Corporation (HK.1548) is the world‘s leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform and the industrial synthesis biological product platform.

GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech’s business operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland. GenScript Biotech provides premium, convenient and reliable services and products for over 200,000 customers.

As of June 30, 2022, GenScript Biotech had more than 5,500 employees globally, over 38% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript Biotech owns a number of intellectual property rights, including over 190 patents, over 820 pending patent applications and great numbers of trade secrets.

Driven by the corporate mission of “make people and nature healthier through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world. As of December 31, 2022, 76,000 peer-reviewed journal articles worldwide have cited GenScript Biotech’s services and products